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We have established high-throughput lectin-antibody ELISAs to measure diﬀerent glycans on transferrin (Tf) in cerebrospinal
ﬂuid (CSF) using lectins and an anti-transferrin antibody (TfAb). Lectin blot and precipitation analysis of CSF revealed that
PVL (Psathyrella velutina lectin) bound an unique N-acetylglucosamine-terminated N-glycans on “CSF-type” Tf whereas SSA
(Sambucus sieboldiana agglutinin) bound α2,6-N-acetylneuraminic acid-terminated N-glycans on “serum-type” Tf. PVL-TfAb
ELISA of 0.5μL CSF samples detected “CSF-type” Tf but not “serum-type” Tf whereas SSA-TfAb ELISA detected “serum-type” Tf
but not “CSF-type” Tf, demonstrating the speciﬁcity of the lectin-TfAb ELISAs. In idiopathic normal pressure hydrocephalus
(iNPH), a senile dementia associated with ventriculomegaly, amounts of the SSA-reactive Tf were signiﬁcantly higher than
in non-iNPH patients, indicating that Tf glycan analysis by the high-throughput lectin-TfAb ELISAs could become practical
diagnostic tools for iNPH. The lectin-antibody ELISAs of CSF proteins might be useful for diagnosis of the other neurological
diseases.
1.Introduction
CSF(cerebrospinal ﬂuid), which circulates within the ventri-
cles of the brain and subarachnoid space, reﬂects the phys-
iological and pathological conditions of the central nervous
system [1]. In fact, CSF proteins are used as biomarkers to
diagnose neurological diseases such as idiopathic normal
pressure hydrocephalus (iNPH) [2–4]a n dA l z h e i m e r ’ sd i s -
ease (AD) [5, 6] and may predict the disease onset in a pre-
clinical stage [7]. Since iNPH and AD show similar pheno-
types such as dementia and ventriculomegaly, it is diﬃcult
to distinguish the two diseases especially in elderly patients.
Therefore, simultaneous measurements of a battery of iNPH
biomarkersand ADbiomarkerscouldhelpexact diagnosis of
iNPH and AD.
We previously designated Tf-1 and Tf-2 as two isoforms
of transferrin in CSF which are separable by SDS-PAGE
and showed that the Tf-2/Tf-1 ratio is higher in iNPH
patients than in non-iNPH patients [3, 4]. In that study
we used immunoblotting method to detect Tf-1 and Tf-
2, but the low throughput of immunoblotting makes it
impractical for clinical use. Although sandwich ELISA (en-
zyme-linked immunosorbent assay) or latex photometric
immunoassay is high throughput, Tf-1 and Tf-2 cannot be
distinguished by these methods because Tf-1 and Tf-2 are
diﬀerent only in their glycan portion, and the antibodies2 International Journal of Alzheimer’s Disease
against the protein portion of Tf cannot distinguish the two
isoforms.
To establish a high throughputmethod to distinguish Tf-
1 and Tf-2, we developed ELISAs using a combination of
lectins and an anti-Tf antibody (TfAb). Tf-1 has a “CSF-
type” biantennary asialo- and agalacto-complex type N-
glycans with bisecting β1,4-N-acetylglucosamine (GlcNAc)
and core α1,6-Fucose [3, 8], whereas Tf-2 in CSF has a
“serum-type” biantennary N-glycans with α2,6-N-acetyl-
neuraminic acid (NeuAc) [3, 9]. Because of their distinct
terminal sugars, that is, GlcNAc on Tf-1 and α2,6-NeuAc
on Tf-2, we chose PVL (Psathyrella velutina lectin) and SSA
(Sambucus sieboldiana agglutinin) to detect Tf-1 and Tf-2
respectively. Our data showed that the lectin-TfAb ELISAs
distinguish the two isoforms to be quantiﬁed and that the
amounts of SSA-reactive Tf were higher in iNPH patients
than in non-iNPH patients. Our newly established lectin-
TfAb ELISAs are high throughput methods to measure
“glycoforms” of transferrin which might be practical for
clinical use.
2.Materialsand Methods
2.1.Patients. Thisstudyincluded28iNPHpatientscompris-
ing 14 males and 14 females aged 75.2 ± 6.1 years (mean ±
SD) and 18 non-iNPH patients comprising 10 males and 8
females aged 74.9 ± 5.2 years [3]. The iNPH patients were
diagnosed using the clinical guidelines for iNPH issued by
the Japanese Society of NPH [10]. A bolus infusion test and
the tap test were performed routinely. Patients whose gait
disturbanceimprovesafterthetaptest,which removes30mL
of CSF via a lumbar puncture, were treated with a shunt
operation. Those who showed symptomatic improvement
1 month after the shunt operation were deﬁned as iNPH
patients while those who did not were deﬁned as non-iNPH
patients. In addition, those who did not show improvement
after the tap test were classiﬁed as non-iNPH patients. The
study was approved by the ethics committee of Fukushima
MedicalUniversity(No.613),which isguidedbylocalpolicy,
national law, and the World Medical Association Declaration
of Helsinki.
2.2. Immunoblotting and Lectin Blotting. CSF samples were
dissolved in Laemmli buﬀer, boiled for 3min, and loaded
onto SDS-polyacrylamide gels (SuperSep Ace; Wako Pure
Chemical Industries, Osaka, Japan). After SDS-PAGE, the
proteinswere transferred to a nitrocellulose membrane (Bio-
Rad Laboratories, Hercules, Calif, USA). The membrane
was blocked in 3% skim milk
￿ incubated sequentially
with an anti-transferrin antibody (Bethyl Laboratories,
Montgomery, Tex, USA) and a horseradish peroxidase-
labeled anti-goat IgG (Jackson ImmunoResearch Laborato-
ries, West Grove, Pa, USA), and developed using a Super
Signal West Dura Extended Duration Substrate (Pierce
Biotechnology, Rockford, Ill, USA). For lectin blotting,
the transferred membrane was blocked in 1% BSA, incu-
bated with a biotinylated PVL or biotinylated SSA (Seika-
gaku Corporation, Tokyo, Japan) followed by a horseradish
peroxidase-labeled streptavidin (Takara, Shiga, Japan), and
developed.
2.3. Lectin Precipitation. CSF was incubated with SSA-aga-
rose (Seikagaku Corporation), and the bound proteins were
precipitated by centrifugation. The unbound proteins were
further incubated with PVL-agarose (Seikagaku Corpora-
tion), and the bound proteins were precipitated.
2.4. Puriﬁcation of Tf-1. Tf-1 was puriﬁed from human CSF
as described before [3]. Brieﬂy, CSF was applied to a HiTrap
Blue HP column (GE Healthcare, Buckinghamshire, UK).
The unbound proteins were applied to a HiTrap Q HP
column (GE Healthcare). The bound proteins were eluted
with a linear gradient of NaCl from 0 to 300mM. Tf-1 was
eluted at 130mM NaCl. Tf-1 was further puriﬁed by rechro-
matography with a HiTrap Q HPcolumn. The concentration
of the puriﬁed Tf-1 was determined by immunoblot analysis
with commercially available human Tf (Sigma-Aldrich, St.
Louis, Mo, USA) as the standard.
2.5. Lectin-Antibody ELISAs. For PVL-TfAb ELISA, a 96-
well C8 Maxisorp Nunc immuno module plate (Nunc,
Roskilde, Denmark) was coated with 2.5μg PVL (Seikagaku
corporation) at 4◦C overnight and blockedwith 0.4% Block-
Ace (Dainippon Sumitomo Pharma, Osaka). Puriﬁed Tf-1
was used as the standard. The standards and CSF samples
were appropriately diluted with PBST (phosphate-buﬀered
saline/0.05% Tween-20), applied to the plate, and incubated
at 4◦C overnight. After three washes with PBST, the plate
was incubated sequentially with anti-Tf antibody (Bethyl
laboratories, Montgomery, Tex, USA) and horseradish
peroxidase-labeled anti-goat IgG (Jackson ImmunoResearch
Laboratories, West Grove, Pa, USA). After three washes with
PBST, the wells were incubated with TMB solution (Wako,
Osaka, Japan), and 1NHCl was added to stop the reaction.
Absorbancesat450nmweremeasuredbyaplatereader(Bio-
Rad Laboratories). CV (Coeﬃc i e n to fv a r i a t i o n )o fP V L -
ELISA was 5.36%.
For SSA-TfAb ELISA, anti-Tf antibodies (Cappel; ICN
Pharmaceuticals, Aurora, Ohio, USA) were pretreated with
1.4mM sodium periodate to abolish SSA epitopes on the
antibody and coated on a 96-well plate. Human reference
serum (Bethyl laboratories) containing 3mg/mL serum Tf
was used as the standard. The standards and CSF samples
were appropriately diluted with TBS (Tris-buﬀered saline)
containing 0.05% Tween 20 and 0.5mM EDTA and applied
to the plate and incubated at 4◦Co v e r n i g h t .A f t e rt h r e e
washes with TBST, the plate was incubated sequentially with
a biotin-SSA (Seikagaku Corporation) and a horseradish
peroxidase-labeled streptavidin (Takara). After three washes
with TBST, the plate was incubated with the TMB substrate,
and the absorbances at 450nm were measured. CV of SSA-
ELISA was 3.65%.
2.6. Statistical Analysis. Data were analyzed with SPSS ver-
sion 17 (SPSS, Chicago, Ill, USA). Amounts of SSA-Tf andInternational Journal of Alzheimer’s Disease 3
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Figure1:PVLandSSAspeciﬁcallydetect Tf-1andTf-2,respectively. (a)CSFwaselectrophoresed, blotted,andstainedwithanti-Tfantibody
(left panel), PVL (center panel), and SSA (right panel). (b) CSF (input) was sequentially precipitated by SSA-agarose and PVL-agarose. The
bound and unbound proteins were electrophoresed and immunoblotted by anti-Tf antibody.
PVL-Tf were analyzed by the Student’s t-test and Mann-
Whitney U test, respectively.
3.Results
To establish high throughput lectin-TfAb ELISAs that dis-
tinguish “CSF-type” Tf-1 and “serum-type” Tf-2, we ﬁrst
examined whether PVL and SSA speciﬁcally detect glycans
on Tf-1 and Tf-2, respectively, by lectin-blotting. As we
reported previously by immunoblotting, Tf-1 and Tf-2 in
CSFwere separated onSDS-gel (Figure 1(a) left). When PVL
was used as a probe, a band with similar mobility to Tf-
1w a sd e t e c t e di nC S F( Figure 1(a) center), suggesting that
PVL speciﬁcally detectsthe terminal GlcNAcon Tf-1 but not
sugars on Tf-2. In contrast, when SSA was used as a probe,
a band with similar mobility to Tf-2 was detected in CSF
(Figure 1(a) right), suggesting that SSA, detects the terminal
α2,6-NeuAc on Tf2 but not sugars on Tf-1. These band
signals detected by PVL and SSA (Figure 1(a) center and
right) were depleted by TfAb (data not shown), suggesting
that the glycan epitopes detected by PVL and SSA reside on
the Tf core protein. Moreover, when CSF was precipitated
sequentially by SSA- and PVL-agarose, Tf-2 was speciﬁcally
recognized by SSA, and Tf-1 was recognized by PVL
(Figure 1(b)). Taken together, PVL and SSA can recognize
Tf-1 and Tf-2, respectively, and distinguish the two Tf glyco-
isoforms.
Next we investigated whether Tf-1 and Tf-2 were specif-
ically detected by PVL-TfAb ELISA and SSA-TfAb ELISA
systems, respectively (Figures 2(a) and 2(b)). The puriﬁed
T f - 1w a su s e da sas t a n d a r dt om e a s u r eT f - 1i nC S Fb yP V L -
TfAb ELISA, whereas Tf in serum was used as a standard
to measure Tf-2 by SSA-TfAb ELISA, since serum contains
only “serum-type” Tf with very similar glycans to Tf-2 [3].
As shown in Figure 2(c), the puriﬁed Tf-1 was successfully
detectedina dose-dependentmanner (4–64ng/mL)byPVL-
TfAbELISA,butnosigniﬁcant signals were detectedwith the
serum Tf, indicating that the PVL-TfAb ELISA speciﬁcally
detects Tf-1. Moreover, SSA-TfAb ELISA detected serum
Tf (4–64ng/mL) but not the puriﬁed Tf-1 (Figure 2(d)),
suggesting speciﬁcity of the SSA-TfAb ELISA for serum Tf
and Tf-2. Tfs which were detected by PVL-TfAb ELISA and
SSA TfAb ELISA were designated as PVL-Tf and SSA-Tf,
respectively.
Finally we measured the concentrations of PVL-Tf and
SSA-Tf in CSF from iNPH and non-iNPH patients. As
shown in Figure 3, amounts of SSA-Tf were signiﬁcantly
increased in iNPH patients compared to non-iNPH patients
while amounts of PVL-Tf were not signiﬁcantly diﬀerent
suggesting that the SSA-Tf might be an iNPH marker. The
SSA-Tf/PVL-Tf ratio were also increased in iNPH patients
(not shown), which is consistent with our previous data
[3].
4.Discussion
In this study we have developed the high throughput lectin-
TfAb ELISAs to measure Tf isoforms that have diﬀerent
terminal sugars. PVL-TfAb ELISA successfully detected Tf-1
but not Tf-2 whereas SSA-TfAb ELISA detected Tf-2 but not
Tf-1, demonstrating that the lectin-TfAb ELISAs distinguish
the two Tf isoforms to be quantiﬁed. Application of the
method to iNPH patients revealed that amounts of SSA-
Tf were signiﬁcantly higher in patients with iNPH than
in those without, suggesting that the lectin-TfAb ELISAs
are promising high throughput methods for diagnosing
iNPH. It would be interesting if the SSA-Tf or PVL-Tf is a
diagnostic marker for AD or the Tfs can distinguish AD and
iNPH.
The lectin-TfAb ELISAs have two diﬀerences compared
to our previously developed immunoblotting method. First,
the lectin-TfAb ELISA is more suitable for clinical use
because the ELISA can process more samples. Second,
the lectin-TfAb ELISAs detect amounts and structures
of glycans on Tf while the immunoblot detects Tf core
protein. The immunoblot is a well-established method for
discovering biomarkers, but most glycoforms of CSF pro-
teins, in contrast with Tf glycoforms, are not separable by4 International Journal of Alzheimer’s Disease
Tf-2
sTf
TfAb
PVL
Tf-1
PVL
(a)
Tf-1
Tf-2
sTf
TfAb
SSA
SSA
(b)
O
D
4
5
0
n
m
Tf (ng/mL)
0.5
1
1.5
2
2.5
0 1 02 03 04 05 06 07 0
Tf-1
sTf
(c)
O
D
4
5
0
n
m
Tf (ng/mL)
0.5
1
1.5
2
2.5
0 1 02 03 04 05 06 07 0
Tf-1
sTf
(d)
Figure 2: PVL-TfAb ELISA and SSA-TfAb ELISA speciﬁcally detect Tf-1 and Tf-2/serum Tf (sTf), respectively. (a) and (b). Schematic
representation of lectin-TfAb ELISAs. PVL-TfAb ELISA (a) detects only Tf-1 while SSA-TfAb ELISA (b) detects only Tf-2/sTf. Closed
triangles and rectangles represent “CSF-type” and “serum-type” glycans on Tf, respectively. (c) and (d) both the puriﬁed Tf-1 and serum
Tf were measured in PVL-Tf ELISA (c) and SSA-TfAb ELISA (d). ODs at 450nm were plotted at each concentration of each Tf. Closed and
opened circles show the Tf-1 and serum Tf, respectively.
SDS-PAGE (unpublished observation). In such cases, the
lectin-antibody ELISAs are more useful to detect speciﬁc
glycoforms than immunoblotting. Based on the concept
that searches for biomarkers should involve not only “pro-
teomics” but also “glycoproteomics” [11, 12], we are cur-
rently trying to develop ELISAs using various combinations
of lectins and antibodies and to ﬁnd new glycobiomarkers
for iNPH as well as other neurological diseases such as
AD.
5.Conclusion
We have developed the PVL-TfAb ELISA and SSA-TfAb
ELISA to measure Tf-1 and Tf-2, respectively. Amounts of
the SSA-reactive Tf were signiﬁcantly higher in CSF of iNPH
patients than in non-iNPH patients, suggesting that the lec-
tin-TfAb ELISAs are promising high throughput methods
for diagnosing iNPH. The lectin-antibody ELISAs might be
useful for a CSF biomarker study of neurological diseases.International Journal of Alzheimer’s Disease 5
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Figure 3: The SSA-Tf is increased in iNPH patients. Concentrations of SSA-Tf (a) and PVL-Tf (b) were measured in CSF of non-iNPH
(n = 18) and iNPH (n = 28) patients, and box plots were shown. An asterisk indicates signiﬁcantlydiﬀerent (P<0.0 5 ) .A no p e na n dc l o s e d
circle represent an outlier and an extreme value, respectively.
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